Aphios
Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.
Aphios
Patents
Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
2020-11-10 • US-10828276-B2
View DetailsWhat We Do
Developing enhanced therapeutics for treating cancers, infectious diseases, and CNS disorders, as well as quality-of-life medicines and research chemicals.
An enhanced ginger product for treating chemotherapy-induced nausea and vomiting, recently completed a successful Phase 2/3 clinical trial.
A non-toxic Vitamin D3 analog for hormone-refractory prostate cancer, designed to have increased antiproliferative effects while reducing systemic toxicity.
A Taxotere® prodrug encapsulated in biodegradable polymer nanospheres to enhance oral bioavailability for chronic chemotherapy.
A combination of a Taxotere® prodrug and monoclonal antibody targeted to treat metastatic cancer.
A nanosomal formulation of paclitaxel for treating Kaposi’s sarcoma and skin cancers.